Could ViRexx Medical’s ‘Linked Recognition’ Research Lead to a Cancer Vaccine?
Dr. Lorne Tyrrell pioneered lamivudine as the standard treatment for hepatitis B virus (HBV). Now a success, he observed the drug’s shortcomings. Now CEO of ViRexx Medical, Tyrrell hopes his latest development, Chimigen, will offer new hope for HBV, other infectious diseases, and cancer.